Inspired to Be Informed
There was no significant difference in overall survival (meaning the time patients started the study to the time of death by any cause) between the women in the AROMASIN® (exemestane tablets) group and the women in the tamoxifen group.
The Intergroup Exemestane Study (IES)
The IES involved 4,724 women past menopause who were on tamoxifen for 2 to 3 years before beginning the study
- 2,352 women were randomized to receive AROMASIN and 2,372 were randomized to stay on tamoxifen
- A comparison between the 2 groups took place at 3 years (34.5 months) and again at 10 years (120 months)